Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,689
  • Shares Outstanding, K 6,311
  • Annual Sales, $ 1,500 K
  • Annual Income, $ -12,960 K
  • EBIT $ -15 M
  • EBITDA $ -15 M
  • 60-Month Beta 1.23
  • Price/Sales 4.32
  • Price/Cash Flow N/A
  • Price/Book 0.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.11
  • Number of Estimates 1
  • High Estimate -0.11
  • Low Estimate -0.11
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +77.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9602 +10.39%
on 12/03/25
1.3300 -20.30%
on 11/06/25
-0.2520 (-19.21%)
since 11/05/25
3-Month
0.9602 +10.39%
on 12/03/25
1.6900 -37.28%
on 10/20/25
-0.4900 (-31.61%)
since 09/05/25
52-Week
0.9602 +10.39%
on 12/03/25
5.0000 -78.80%
on 01/03/25
-2.1000 (-66.46%)
since 12/05/24

Most Recent Stories

More News
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

APR-1051 (WEE1 kinase inhibitor): In ongoing Phase 1 ACESOT-1051dose-escalation trial, 3 out of 4 patients at Dose Level 6 (100 mg once daily) achieved stable disease, per RECIST v1.1, in heavily pretreated...

APRE : 1.0600 (unch)
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignancies Disease stabilization observed in patients...

APRE : 1.0600 (unch)
Aprea Therapeutics Shifts Focus to Combination Therapies

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Aprea Therapeutics...

APRE : 1.0600 (unch)
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

ATRN-119 (ATR Inhibitor): RP2D of 1,100 mg once daily identified in ongoing ABOYA-119 dose-escalation study Further ATRN-119 monotherapy enrollment paused with strategic focus on high-value combination...

APRE : 1.0600 (unch)
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

DOYLESTOWN, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments...

APRE : 1.0600 (unch)
Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference

DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments...

APRE : 1.0600 (unch)
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

Early evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts treated with the   WEE1 inhibitor,...

APRE : 1.0600 (unch)
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

APRE : 1.0600 (unch)
Artios' AACR Data Success: What It Means for Aprea Therapeutics' ATRN-119 Program

Discover how Artios Pharma's "game-changing" ATR inhibitor trial success validates this cancer treatment strategy, boosting prospects for Aprea Therapeutics' similar drug and offering hope for ATM-deficient...

APRE : 1.0600 (unch)
This Under-The-Radar Cancer Biotech Reports 21% Tumor Shrinkage: Analysts See 600%+ Upside

A clinical-stage biotech company focused on synthetic lethality has reported promising progress across its cancer drug pipeline, highlighted by early signs of tumor reduction in multiple patients, with...

APRE : 1.0600 (unch)

Business Summary

Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, p53. The Company's lead drug candidate, APR-246, a first-in-class small molecule p53 reactivator, is in clinical development...

See More

Key Turning Points

3rd Resistance Point 1.1367
2nd Resistance Point 1.1133
1st Resistance Point 1.0867
Last Price 1.0600
1st Support Level 1.0367
2nd Support Level 1.0133
3rd Support Level 0.9867

See More

52-Week High 5.0000
Fibonacci 61.8% 3.4568
Fibonacci 50% 2.9801
Fibonacci 38.2% 2.5034
Last Price 1.0600
52-Week Low 0.9602

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar